UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1

Arteriosclerosis, thrombosis, and vascular biology, 2013-07, Vol.33 (7), p.1484-1493

2013

Volltextzugriff (PDF)

Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets

Nutrition & metabolism, 2013-01, Vol.10 (1), p.4-4

2013

Volltextzugriff (PDF)

Hepatic PCSK9 Expression Is Regulated by Nutritional Status via Insulin and Sterol Regulatory Element-binding Protein 1c

The Journal of biological chemistry, 2006-03, Vol.281 (10), p.6211-6218

2006

Volltextzugriff (PDF)

Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia

Arteriosclerosis, thrombosis, and vascular biology, 2009-05, Vol.29 (5), p.684-690

2009

Volltextzugriff (PDF)

Specific Binding of ApoA-I, Enhanced Cholesterol Efflux, and Altered Plasma Membrane Morphology in Cells Expressing ABC1

The Journal of biological chemistry, 2000-10, Vol.275 (42), p.33053-33058

2000

Volltextzugriff (PDF)

Regulation and mechanisms of macrophage cholesterol efflux

The Journal of clinical investigation, 2002-10, Vol.110 (7), p.899-904

2002

Volltextzugriff (PDF)

PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia

Arteriosclerosis, thrombosis, and vascular biology, 2009-12, Vol.29 (12), p.2191-2197

2009

Volltextzugriff (PDF)

Is atrial fibrillation in HFpEF a distinct phenotype? Insights from multiparametric MRI and circulating biomarkers

BMC cardiovascular disorders, 2024-02, Vol.24 (1), p.94-94, Article 94

2024

Volltextzugriff (PDF)

Fasting Induces Hyperlipidemia in Mice Overexpressing Proprotein Convertase Subtilisin Kexin Type 9: Lack of Modulation of Very-Low-Density Lipoprotein Hepatic Output by the Low-Density Lipoprotein Receptor

Endocrinology (Philadelphia), 2006-10, Vol.147 (10), p.4985-4995

2006

Volltextzugriff (PDF)

Dual Mechanisms for the Fibrate-mediated Repression of Proprotein Convertase Subtilisin/Kexin Type 9

The Journal of biological chemistry, 2008-04, Vol.283 (15), p.9666-9673

2008

Volltextzugriff (PDF)

Molecular pathways and agents for lowering LDL-cholesterol in addition to statins

Pharmacology & therapeutics (Oxford), 2010-06, Vol.126 (3), p.263-278

Costet, Philippe

2010

Volltextzugriff (PDF)

Impact of diabetes on remodelling, microvascular function and exercise capacity in aortic stenosis

Open heart, 2023-08, Vol.10 (2), p.e002441

2023

Volltextzugriff (PDF)

Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients

Atherosclerosis, 2010-08, Vol.211 (2), p.700-702

2010

Volltextzugriff (PDF)

Retinoic Acid Receptor-Mediated Induction of ABCA1 in Macrophages

Molecular and Cellular Biology, 2003-11, Vol.23 (21), p.7756-7766

2003

Volltextzugriff (PDF)

Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells

Journal of lipid research, 2005-06, Vol.46 (6), p.1312-1319

2005

Volltextzugriff (PDF)

Clinical aspects of PCSK9

Atherosclerosis, 2011-06, Vol.216 (2), p.258-265

2011

Volltextzugriff (PDF)

PCSK9: a promising therapeutic target for dyslipidemias?

Trends in endocrinology and metabolism, 2006-04, Vol.17 (3), p.79-81

2006

Volltextzugriff (PDF)

PCSK9 and LDL cholesterol: unravelling the target to design the bullet

Trends in biochemical sciences (Amsterdam. Regular ed.), 2008-09, Vol.33 (9), p.426-434

2008

Volltextzugriff (PDF)

First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-986308: A Renal Outer Medullary Potassium Channel Inhibitor

Clinical pharmacology and therapeutics, 2024-09

2024

Volltextzugriff (PDF)

Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor

The Journal of biological chemistry, 2000-09, Vol.275 (36), p.28240-28245

2000

Volltextzugriff (PDF)

PCSK9 is expressed in pancreatic δ-cells and does not alter insulin secretion

Biochemical and biophysical research communications, 2009-12, Vol.390 (4), p.1288-1293

2009

Volltextzugriff (PDF)

Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9

Arteriosclerosis, thrombosis, and vascular biology, 2004-08, Vol.24 (8), p.1448-1453

2004

Volltextzugriff (PDF)

Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes

FEBS letters, 2008-03, Vol.582 (6), p.949-955

2008

Volltextzugriff (PDF)

Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes

Atherosclerosis, 2011-11, Vol.219 (1), p.342-348

2011

Volltextzugriff (PDF)

Regulation and mechanisms of macrophage cholesterol efflux

The Journal of clinical investigation, 2002-10, Vol.110 (7), p.899-904

2002

Volltextzugriff (PDF)

1 – 25 von 91

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(87)
Mit Volltextzugriff
(80)

Publikationsform

Artikel
(90)
Buchkapitel
(1)

Sprache

Englisch
(87)
Französisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1

Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets

Hepatic PCSK9 Expression Is Regulated by Nutritional Status via Insulin and Sterol Regulatory Element-binding Protein 1c

Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia

Specific Binding of ApoA-I, Enhanced Cholesterol Efflux, and Altered Plasma Membrane Morphology in Cells Expressing ABC1

Regulation and mechanisms of macrophage cholesterol efflux

PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia

Is atrial fibrillation in HFpEF a distinct phenotype? Insights from multiparametric MRI and circulating biomarkers

Fasting Induces Hyperlipidemia in Mice Overexpressing Proprotein Convertase Subtilisin Kexin Type 9: Lack of Modulation of Very-Low-Density Lipoprotein Hepatic Output by the Low-Density Lipoprotein Receptor

Dual Mechanisms for the Fibrate-mediated Repression of Proprotein Convertase Subtilisin/Kexin Type 9

Molecular pathways and agents for lowering LDL-cholesterol in addition to statins

Impact of diabetes on remodelling, microvascular function and exercise capacity in aortic stenosis

Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients

Retinoic Acid Receptor-Mediated Induction of ABCA1 in Macrophages

Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells

Clinical aspects of PCSK9

PCSK9: a promising therapeutic target for dyslipidemias?

PCSK9 and LDL cholesterol: unravelling the target to design the bullet

First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-986308: A Renal Outer Medullary Potassium Channel Inhibitor

Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor

PCSK9 is expressed in pancreatic δ-cells and does not alter insulin secretion

Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9

Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes

Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes

Regulation and mechanisms of macrophage cholesterol efflux

Suchergebnisse filtern